No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EW240621P87500
- 1.25
- -0.05-3.85%
15min DelayClose Jun 14 15:59 ET
1.40High1.25Low
1.40Open1.30Pre Close12 Volume673 Open Interest87.50Strike Price1.57KTurnover25.06%IV1.19%PremiumJun 21, 2024Expiry Date0.21Intrinsic Value100Multiplier5DDays to Expiry1.04Extrinsic Value100Contract SizeAmericanOptions Type-0.5151Delta0.1453Gamma74.29Leverage Ratio-0.0931Theta-0.0065Rho-38.26Eff Leverage0.0439Vega
Intraday
- 5D
- 1D
News
Edwards Lifesciences(EW.US) Officer Sells US$437.7K in Common Stock
$Edwards Lifesciences(EW.US)$ Officer BOBO DONALD E JR sold 5,000 shares of common stock on Jun 12, 2024 at an average price of $87.5393 for a total value of $437.7K.Source: Announcement What is state
Form 144 | Edwards Lifesciences(EW.US) Insider Proposes to Sell 8.03 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 11, $Edwards Lifesciences(EW.US)$ Insider Michael A. Mussallem intends to sell 92,300 shares of its common stock on Jun 11, with a total market value of approximately $8.03
HOLX Vs. EW: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Hologic (HOLX) or Edwards Lifesciences (EW).
Jefferies Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $102
Jefferies analyst Matthew Taylor maintains $Edwards Lifesciences(EW.US)$ with a buy rating, and maintains the target price at $102.According to TipRanks data, the analyst has a success rate of 60.3% a
TD Cowen Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $100
TD Cowen analyst Josh Jennings maintains $Edwards Lifesciences(EW.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 52.4% and
Express News | NYSE Order Imbalance 65222.0 Shares on Sell Side
Comments
Edwards Lifesciences' impressive ROCE history and its ability to generate high returns on increasing amounts of capital employed indicate strong fundamentals. This warrants further research into the stock despite it being more 'expensive' than before.
Edwards Lifesciences (NYSE:EW) Is Aiming To Keep Up Its Impressive ReturnsAnalysts reconfirmed revenue and earnings forecasts for Edwards Lifesciences, indicating no major change in business expectations following recent results. The price target increase suggests analysts believe the business's intrinsic value is improving.
Investors banking on Edwards Lifesciences' high P/E ratio might face a challenge as the firm's predicted market-aligned growth hints at a potential share price decline.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Align Technology(ALGN.US$ - up 11.5%
2. $Textron(TXT.US$ - up 5.2%
3. $STMicroelectronics(STM.US$ - up 4.1%
4. $Lam Research(LRCX.US$ - up 3.9%
5. $RELX PLC(RELX.US$ - up 3.1%
6. $Royal Caribbean(RCL.US$ - up 3.1%
7. $Micron Technology(MU.US$ - up 3.1%
8. $Western Digital(WDC.US$ - up 2.9...
Gap Ups
1. $Align Technology(ALGN.US$ - up 11.5%
2. $Textron(TXT.US$ - up 5.2%
3. $STMicroelectronics(STM.US$ - up 4.1%
4. $Lam Research(LRCX.US$ - up 3.9%
5. $RELX PLC(RELX.US$ - up 3.1%
6. $Royal Caribbean(RCL.US$ - up 3.1%
7. $Micron Technology(MU.US$ - up 3.1%
8. $Western Digital(WDC.US$ - up 2.9...
+17
18
Pre-Market Stock Movers
Gapping up
$Align Technology(ALGN.US$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$Meta Platforms(META.US$
(The Facebook parent jumped ne...
Gapping up
$Align Technology(ALGN.US$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$Meta Platforms(META.US$
(The Facebook parent jumped ne...
17
Read more